Shares of Apricus Biosciences Inc. (NASDAQ:APRI) have been given an average recommendation of “Hold” by the six research firms that are presently covering the company. Four research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $2.32.
Separately, Zacks Investment Research downgraded Apricus Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday.
Shares of Apricus Biosciences (NASDAQ:APRI) traded down 5.5460% on Wednesday, reaching $0.3287. 397,720 shares of the company were exchanged. Apricus Biosciences has a 52 week low of $0.30 and a 52 week high of $1.99. The stock’s market capitalization is $20.32 million. The firm’s 50 day moving average price is $0.39 and its 200 day moving average price is $0.71.
Apricus Biosciences (NASDAQ:APRI) last released its quarterly earnings results on Monday, May 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). During the same period last year, the company posted ($0.13) EPS. Equities research analysts anticipate that Apricus Biosciences will post ($0.18) EPS for the current year.
Apricus Biosciences, Inc is a pharmaceutical company focused on the development and commercialization of products and product candidates in the areas of specialty urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has one approved drug, Vitaros, which uses the NexACT delivery system, and is approved for the treatment of erectile dysfunction (ED) in Canada and through the European Decentralized Procedure (DCP) in Europe.
